On 4/1/24, Zevra Therapeutics Inc (NASDAQ: ZVRA) stock suffered a major decline of -11.0%, closing at $5.16. Moreover, trading volume in this decline was exceptionally high at 240% of normal. The stock has declined -11.6% during the last week but has been exceptionally strong relative to the market over the last nine months.
Current PriceTarget Research Rating
ZVRA is expected to continue to be Value Creation neutral reflecting capital returns that are forecasted to be in line with the cost of capital.
Zevra Therapeutics has a current Value Trend Rating of D (Negative). The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Zevra Therapeutics has a very low Appreciation Score of 3 but a good Power Rating of 78, producing the Negative Value Trend Rating.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment